Merck· @Merck · X·· 2026-06-25精选AI 评分62
AI 导读
默沙东宣布，其与吉利德合作的两款免疫治疗联合方案获FDA批准，用于部分晚期三阴性乳腺癌（TNBC）成人患者。默沙东称这是该疾病治疗的重要进展，更多信息见 http://go.merck.com/~y66。
推荐理由
默沙东与吉利德合作的免疫联合方案获FDA批准用于晚期三阴性乳腺癌，读者可了解该适应症新增的治疗选择。
正文
We’re proud to announce the #FDA approvals of two new immunotherapy-based treatment combinations for certain adults with advanced triple negative breast cancer (#TNBC). This milestone, in collaboration with @GileadSciences, is an important step forward in care for patients with this disease.
Learn more: http://go.merck.com/~y66
来源：Merck · x.com